Low oral (1-2.5 mg/day)

"Subtle to imperceptible" is the modal report. Some users report mild mood-lift, slightly enhanced drive/libido, less afternoon flatness — typically over 2-6 weeks of daily use, not acute. No "you can feel it kicking in" character. Doesn't feel like a stimulant. Tolerable for most. Insomnia risk is real but mostly avoided by AM-only dosing.

Emsam 6 mg/24hr patch

Onset over 1-3 weeks. Reports: gradual mood lift, increased motivation/drive, reduced anhedonia, improved libido. Generally well-tolerated. The "always on" steady-state delivery (vs the daily-pulsed oral) feels different — less peaks, more sustained baseline shift. No dietary restriction at this tier. Common subjective: skin irritation at the patch site (15-25% in trials).

Emsam 9-12 mg/24hr patch

Reported as transformative by some users — the original external source claim "best thing ever" tracks at this tier. Stronger antidepressant effect, enhanced cognition by serotonin + dopamine + norepinephrine elevation simultaneously, MAOI-class mood lift. Caveat: the "slice of cheese could kill them" warning is also accurate at this tier. Users report constant low-grade dietary anxiety. Lifestyle constraint is significant — restaurants become a calculation, sauces become unknowable, accidentally eating an aged cheese gives you a window of fear before knowing if you'll get a hypertensive spike. NOT a dose tier you adopt casually.

• Tolerance buildup: Minimal at low oral dose. The standard nootropic-community framing is "no significant tolerance" and that's roughly accurate. Mechanism: MAO-B regenerates over ~40-day half-life, so steady-state inhibition is reached after ~6 weeks of daily dosing and stays there. Receptor downregulation is not a major tolerance mechanism here (see "no receptor downregulation" discussion in Mechanism section).
• Recommended cycle: Daily indefinite at low oral. No cycling needed. Some users do 5-on / 2-off weekly to add tolerance insurance — not evidence-based but harmless.
• Reset protocol: ~2-3 weeks washout if any reset desired. Full MAO-B regeneration takes ~6 weeks.

The "no receptor downregulation" claim — verification verdict

Mechanistically accurate at the low-oral tier. Selegiline's primary MoA (enzyme inhibition + TAAR1 weak agonism) does not produce the supraphysiologic synaptic flooding that drives D2 receptor downregulation in chronic amphetamine use. Animal data and the limited human DAT-imaging data (one PMC study) support this claim. The claim degrades at the 9-12 mg patch / >10 mg oral tier because L-amphetamine metabolite levels rise to clinically relevant amphetaminergic levels — but at those tiers tolerance/downregulation is the LEAST of your concerns vs the tyramine cliff.

Synergistic with

• modafinil: Different mechanisms (DA-tone preservation via MAO-B vs DA reuptake inhibition + histamine + orexin). Stack is widely reported clean in the nootropic community. Modafinil + low-dose selegiline is in the canonical stack plan and the encyclopedia stacking section explicitly endorses this combination.
• bromantane: Cleanly orthogonal — bromantane upregulates DA synthesis at the TH/AAAD level + raises brain GSH; selegiline preserves what's already there. No mechanism overlap, no shared liability.
• l-tyrosine: PRN under cognitive stress. Tyrosine provides substrate, selegiline preserves the resulting DA. Synergistic within a stress-response window.
• ALCAR: Mitochondrial support for DA neurons + selegiline's enzymatic preservation = compounding neuroprotection mechanisms. Mild synergy.
• astaxanthin / DHA / NAC: Antioxidant/membrane support for the DA neurons selegiline is preserving. Generally additive.
• bpap / ppap: These are next-gen TAAR1-selective enhancers without MAO inhibition. THEORETICALLY synergistic with selegiline at low dose (different mechanisms) but the rational move would be to choose ONE: if MAO-B inhibition is wanted, low-dose selegiline; if pure CAE without MAO inhibition is wanted, BPAP.

Avoid stacking with

• bupropion (Wellbutrin): Increases dopaminergic activity (NDRI). Combined with MAO-B inhibitor not formally contraindicated at low selegiline dose, but introduces risk of hypertension + agitation. At 6+ mg patch it is contraindicated. Per the canonical stack plan, bupropion is an alternative-path choice — pick one or the other, not both.
• SSRIs / SNRIs: Serotonin syndrome risk. At low-oral selegiline (1-2.5 mg) the risk is lower than at higher tiers — there are studies (PMC6019085) showing 4500+ PD patients on selegiline + antidepressant with only 11 cases serotonin syndrome and zero fatalities — but the FDA labels both Zelapar and Emsam as contraindicated with SSRIs.
• MDMA, methamphetamine, cocaine, MAOIs (other), amphetamine high-dose: Catastrophic combinations.
• other MAO-B or MAO-A inhibitors (rasagiline, phenelzine, tranylcypromine, isocarboxazid, linezolid, methylene blue): redundant + dangerous.
• St. John's Wort / 5-HTP / L-tryptophan in high dose: serotonin syndrome risk at higher selegiline tiers. Note: the canonical stack plan includes L-tryptophan 1g pre-bed as a sleep adjunct. At 1-2.5 mg oral selegiline morning + L-tryptophan 1g night this should be fine (low tier + temporal separation + low dose tryptophan), but at any patch tier this would need re-evaluation.
• adderall / vyvanse / dexedrine: at low oral selegiline risk is moderated; at any patch tier contraindicated.
• DXM (dextromethorphan): contraindicated. Cough syrups containing DXM must be avoided. Use guaifenesin-only or codeine-only alternatives.
• tramadol, meperidine (Demerol), methadone, fentanyl-class: contraindicated. Standard non-serotonergic opioids (morphine, oxycodone, hydromorphone) are generally OK but use caution.

Neutral / safe co-administration

• Caffeine — no meaningful interaction at usual doses
• Creatine — neutral
• Citicoline / Alpha-GPC / DHA / PS — neutral, possibly mildly additive on cognition
• Magnesium / Vitamin D / K2 / NAC — neutral
• Selank / Semax / Adamax (Russian peptides) — no evidence of interaction; mechanistic distance suggests safe co-admin
• Apigenin — some MAO-A inhibition theoretically, but at supplement doses not clinically meaningful with low-oral selegiline; cleaner with Emsam tiers if at all
• Theanine, glycine, taurine, beta-alanine — neutral

Absolute contraindications (do not combine)

• Other MAOIs: phenelzine (Nardil), tranylcypromine (Parnate), isocarboxazid (Marplan), rasagiline (Azilect), safinamide, linezolid (antibiotic), methylene blue (procedural use)
• Meperidine (Demerol) — fatal interactions reported. Tell ER/anesthesiology.
• Tramadol — same fatal interaction class.
• Methadone — contraindicated.
• Dextromethorphan (DXM) — psychosis + serotonin syndrome reports.
• MDMA, methamphetamine — hypertensive crisis + serotonin syndrome.
• Selective serotonin reuptake inhibitors (SSRIs): sertraline (Zoloft), fluoxetine (Prozac), paroxetine (Paxil), citalopram (Celexa), escitalopram (Lexapro), fluvoxamine — formally contraindicated per FDA label. Real-world data suggests citalopram + sertraline are the lower-risk SSRIs IF combination is unavoidable.
• SNRIs: venlafaxine (Effexor), duloxetine (Cymbalta), desvenlafaxine — contraindicated.
• TCAs: amitriptyline, clomipramine, imipramine — contraindicated.
• Bupropion: package label contraindicated; clinical practice sometimes uses with caution at low selegiline dose, but DON'T combine.

Caution / monitor

• Sympathomimetics (pseudoephedrine, ephedrine, phenylephrine OTC): risk of BP elevation. Avoid at high tiers; monitor at low oral.
• CYP2B6 inducers (rifampin, efavirenz, carbamazepine, phenytoin): can lower selegiline + metabolite levels.
• CYP2B6 inhibitors (clopidogrel, ticlopidine, voriconazole, sertraline at higher doses): can raise selegiline + metabolite levels.
• Anesthetics: disclose to anesthesiologist. Some opioids (morphine, fentanyl) require modification of plan.

Tyramine — high-tier only

At 9-12 mg patch (and oral >10 mg) avoid:

• Aged cheeses: cheddar, blue, parmesan, brie, camembert, gouda, gruyère
• Aged/cured meats: salami, pepperoni, prosciutto, dry sausage, soppressata, salt-cured fish
• Fermented soy: soy sauce (in quantity), miso, tofu (aged), tempeh
• Fermented vegetables: sauerkraut, kimchi
• Tap beer / draft beer / red wine (especially Chianti); bottled beer in moderation generally OK
• Fava beans (broad beans)
• Marmite, Vegemite
• Overripe / spoiled food of any kind
• Smoked fish

At 1-2.5 mg oral OR Emsam 6 mg patch: tyramine restrictions are NOT required. This is the central differentiator that makes the low-oral tier "daily-safe normal life" and makes the high-tier "lifestyle commitment."

Primary CYP enzymes

• CYP2B6 — primary metabolizer of selegiline. HIGHLY POLYMORPHIC. Common variants:
  • CYP2B6*6 (G516T + A785G) — reduced enzyme activity. Carriers (~25% of Europeans, ~50% of African ancestry) have higher selegiline parent + lower L-amph/L-meth metabolite levels at given dose. May tolerate higher dose with less amphetaminergic side effect.
  • CYP2B6*4 — increased activity. Faster metabolism, higher metabolite load, possibly more amphetaminergic side effects.
  • CYP2B6*5 — decreased activity.
• CYP2C19 — secondary major contributor. Polymorphism status:
  • *CYP2C192, 3 (poor metabolizers)* — slower clearance.
  • CYP2C19*17 (ultrarapid) — faster clearance.
• CYP3A4 — minor contributor.
• CYP2D6 — NOT important for selegiline metabolism per multiple studies. The standard "CYP2D6 tells you everything about psych drugs" heuristic does NOT apply here.

Dopamine pathway polymorphisms (response prediction)

• COMT Val158Met (rs4680): Met/Met homozygotes have lower COMT activity → naturally higher PFC DA tone. May respond to selegiline differently — possibly less marginal benefit (already DA-rich) and more side effects. Val/Val homozygotes (lower DA tone) may benefit more.
• DRD2/ANKK1 Taq1A (rs1800497): A1 allele carriers have reduced D2 receptor density. May benefit more from DA-preserving compounds like selegiline. Worth checking on the user's 23andMe.
• DRD4 7R repeat: novelty-seeking/impulsivity allele, hypothesized differential response — limited direct selegiline data.
• MAOA-uVNTR (the "warrior gene"): affects MAO-A activity, not directly relevant to MAO-B-selective dose, but at 9-12 mg patch where MAO-A is also inhibited, low-activity MAOA carriers may experience disproportionate effect.

For the user specifically (23andMe results pending June 2026)

Flag these SNPs for review when results land:

1. rs3745274 (CYP2B6*6 G516T): dose response prediction
2. rs2279343 (CYP2B6*6 A785G): companion variant
3. rs4244285 (CYP2C19*2): secondary metabolizer status
4. rs12248560 (CYP2C19*17): ultrarapid metabolizer marker
5. rs4680 (COMT Val158Met): baseline DA tone
6. rs1800497 (DRD2/ANKK1 Taq1A): D2 receptor density baseline
7. rs1799836 (MAOB intron 13): affects MAO-B baseline expression — possibly the most direct selegiline-relevant SNP. Some research suggests differential response to MAO-B inhibitors by MAOB genotype.

These SNPs are typically present on 23andMe v5 chip. Run them through Promethease / Genetic Lifehacks / the GENETICS-PHARMACOGENOMICS.md frame after results arrive.

For the user: clear recommendation = US Rx generic 5 mg capsules + pill cutter (already in the canonical stack). $20-30/mo. Indian pharmacy is the backup if US Rx friction is high.

Baseline (before starting)

• Resting BP + orthostatic BP delta (lying → standing) — establish baseline before MAO inhibition
• HR resting
• Mood self-report scale (PHQ-9 or simpler 0-10)
• Sleep onset latency + total sleep time (Oura/ring data)
• Libido / drive baseline (subjective)
• Liver panel (ALT/AST)
• 23andMe SNP review (CYP2B6, CYP2C19, COMT, DRD2, MAOB) — the user's pending June 2026

During use

• Resting + orthostatic BP weekly first month, monthly thereafter
• Mood + drive self-report weekly
• Sleep metrics ongoing (Oura + subjective)
• Patch site condition (Emsam tier only)
• Watch for any tyramine-like symptoms even at low tier (headache, palpitations) — extremely unlikely but pattern-recognize

Post-cycle (if discontinuing)

• 2-week observation for mood/drive baseline return
• Continue tyramine awareness for 2 weeks (residual MAO inhibition)
• Liver panel if symptomatic